Mesothelioma Patients Survive Longer with Trimodal Treatment

Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote. “Well selected patients seem to benefit from aggressive therapy.” The Journal of Clinical Oncology published the study Aug. 17. The research team utilized the National Cancer Database, a hospital-based nationwide registry that represents an estimated 70 percent of newly-diagnosed cancer cases in the U.S. Trimodal Treatment Works The study began with 20,561 mesothelioma patients identified from 2004 to 2014. Of those, 6,645 were used in a matching cohort, separated into surgical and non-surgical groups. Among the findings, overall median survival was: 8 months for those undergoing trimodal treatment (surgery, chemotherapy and radiation). 9 months for those undergoing surgery 5 months for patients having no surgery Patients with the epithelial histology of mesothelioma fared the best with a median survival of 23.4 months, compared to just 13.7 ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news

Related Links:

This study of women included 275 cases of pleural mesothelioma and 79 cases of peritoneal. Papillary mesothelioma and localized mesothelioma cases were excluded. Previous reports have shown that 22% to 29% of mesothelioma cases involve women, but only 12% in this particular study. Other Notable Takeaways The majority of those studied were exposed to asbestos through household contact. Women who worked in occupations and industries associated with higher asbestos exposure had objective markers of exposure similar to men. Survival was longer for the epithelial subtype of mesothelioma and magnified with the per...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
CONCLUSIONS.—: Highlighted by their relevance in the large cohort reported, we recommend 2 useful panels to the differential diagnosis at 10% cutoff. PMID: 31389715 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Too many patients with pleural mesothelioma are going without treatment recommended by National Comprehensive Cancer Network guidelines, according to a recent study at Cedars-Sinai Medical Center in Los Angeles. Valuable survival time is being lost. The Annals of Thoracic Surgery published the study that looked at disparities in compliance with national treatment guidelines and their impact on overall survival. The National Comprehensive Cancer Network, along with the American Society of Clinical Oncology, recommends multimodal therapy — surgery, chemotherapy and possibly radiation therapy — for mesothelioma pa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study we tested the clinoptilolite, chabazite, and natrolite ability to be loaded by antitumor ribonuclease binase and the cytotoxicity of the obtained complexes. We found the optimal conditions for binase loading into zeolites and established the dynamic of its release. Cytotoxic effects of zeolite-binase complexes toward colorectal cancer Caco2 cells were characterized after 24 and 48 h of incubation with cells using MTT-test. Zeolites were toxic by itselfs and reduced cells viability by 30% (clinoptilolite), 40% (chabazite), and 70% (natrolite) after 48 h of incubation. Binase complexes with clinoptilolite as we...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 April 2019Source: The Annals of Thoracic SurgeryAuthor(s): Fernando Espinoza-Mercado, Jerald D. Borgella, David Berz, Rodrigo F. Alban, Ariella Sarkissian, Taryne A. Imai, Harmik J. SoukiasianAbstractBackgroundCurrent guidelines support cancer-directed surgery, chemotherapy or active surveillance for clinical stages 1 to 3 of epithelial Malignant Pleural Mesothelioma (MPM). Definitive chemotherapy is recommended for sarcomatoid/biphasic histologies. Our objective is to assess compliance with recommendations, measuring their impact on overall survival (OS).MethodsThe National Cancer Dat...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Abstract BACKGROUND: Current guidelines support cancer-directed surgery, chemotherapy or active surveillance for clinical stages 1 to 3 of epithelial Malignant Pleural Mesothelioma (MPM). Definitive chemotherapy is recommended for sarcomatoid/biphasic histologies. Our objective is to assess compliance with recommendations, measuring their impact on overall survival (OS). METHODS: The National Cancer Database participant user file (2004-2014) was queried for patients diagnosed with MPM clinical stages 1 to 3. Multivariable logistic regression model identified factors independently associated with guideline com...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Databases & Libraries | Environmental Health | Epithelial Cancer | Hospitals | Mesothelioma | Radiation Therapy | Study